Long-term follow-up of people treated with gene-modified T cell therapy
Follows people who received gene-modified T cell therapy in an earlier study for cancer.
Key facts
- Who runs it
- Celgene
- Where
- Seoul, South KoreaSee the 4 sitesAlso in 25 other countries, 259 sites
- Trial code
- NCT03435796
- EU 2023-504201-36-00
- EudraCT 2017-001465-24
- U1111-1206-8250
- Registry title
- Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 1,541 people, planned
- Started
- 19 Jul 2018
- Expected to end
- 29 May 2043
- Type of study
- Interventional
- Treatments tested
- Gene-modified (GM) T cell therapy
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults and children who already received at least one infusion of gene-modified T cells in an earlier sponsored trial. It follows their safety and results over the long term.
- Age
- Adults and children. No exact age range is given in the record.
- Sex
- All sexes can join.
- Earlier treatment
- Must have received at least one gene-modified T-cell infusion in an earlier Celgene, Juno Therapeutics, other BMS affiliate or Celgene alliance partner trial. Must have stopped or finished follow-up in that trial.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance partner-sponsored trial, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable
- Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted
Who cannot take part
- Not Applicable
- Other protocol-defined inclusion/exclusion criteria apply
Where in South Korea
Also in 25 other countries, 259 sites
- Asan Medical Center (AMC)Seoul, South KoreaContact: Dok Hyun Yoon, Site 17003Taking people
- Samsung Medical CenterSeoul, South KoreaContact: Kihyun Kim, Site 17001Taking people
- Seoul National University HospitalSeoul, South KoreaContact: YOUNGIL KOH, Site 17006Taking people
- The Catholic University of Korea, Seoul ST. Mary's HospitalSeoul, South KoreaContact: Chang Ki Min, Site 17002Taking people
About the trial
What the trial wants to find out
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.
Read full original descriptionShow less
Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
The group in the trial
- Participants exposed to Gene-modified (GM) T cell therapyOther group
Treatment: Gene-modified (GM) T cell therapy
Results explained
A paper that names this trial, explained in plain words.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
- Plain-language title
- Long-term follow-up of people treated with gene-modified T cell therapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study.Blood, 2026
- Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.Blood, 2026
- Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.Blood, 2024
- Record updated
- 2 November 2026